Biogen Idec To Collaborate With Isis On Treatment For Degenerative Muscle Disorder
This article was originally published in The Pink Sheet Daily
The two companies build on an existing partnership in spinal muscular atrophy to address another muscle-wasting disease. For the second time, they’ve arranged an option deal, with milestones built in both before and after licensing.
You may also be interested in...
The antisense company has made it clear that it will not pursue commercialization of its own drugs, but intends to partner out all of its assets, while still retaining the most advantageous economics. Its fourth agreement with Biogen Idec, a strategic collaboration, is the most extensive and lucrative to date with the partner.
Isis banks on milestones from partners, Onyx rakes in higher-than-expected revenues from Kyprolis, Seattle Genetics announces trial delays, and other news from biopharma’s first quarter.
The biotech’s latest tie-up is another validation of its technology that could help it garner further attention – and better economics – for some of its late-stage programs.